Crizotinib in advanced non-small-cell lung cancer with concomitant ALK rearrangement and c-Met overexpression

OBJECTIVE: Crizotinib can target against mesenchymal-epithelial transition (MET) and anaplastic lymphoma kinase (ALK), which has been considered as a multi-targeted tyrosine kinase inhibitor (TKI). The objective of this study was to explore the efficacy of crizotinib in advanced non-small-cell lung...

Descripción completa

Detalles Bibliográficos
Autores principales: Chen, Rui-Lian, Zhao, Jun, Zhang, Xu-Chao, Lou, Na-Na, Chen, Hua-Jun, Yang, Xue, Su, Jian, Xie, Zhi, Zhou, Qing, Tu, Hai-Yan, Zhong, Wen-Zhao, Yan, Hong-Hong, Guo, Wei-Bang, Wu, Yi-Long, Yang, Jin-Ji
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2018
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6258481/
https://www.ncbi.nlm.nih.gov/pubmed/30477470
http://dx.doi.org/10.1186/s12885-018-5078-y

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6258481/
https://www.ncbi.nlm.nih.gov/pubmed/30477470
http://dx.doi.org/10.1186/s12885-018-5078-y

Ejemplares similares